Transient impairment of peripheral blood lymphocyte function during PUVA therapy

Morison, Warwick L.; Parrish, John A.; Bloch, Kurt J.; Krugler, Joel I.

doi:10.1111/j.1365-2133.1979.tb00016.x

Cited by 44 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, all blood samples were taken at least 4-7 days after the last treatment. Secondly, in a previous study (Morison et al, 1979) of psoriasis patients on maintenance PUVA therapy we did not find such abnormalities. However, patients in this study were examined after only one month of maintenance treatment.…”

Section: Discussionmentioning

confidence: 54%

Abnormal lymphocyte function following long-term PUVA therapy for psoriasis

et al. 1983

View full text Add to dashboard Cite

The surface markers and function of peripheral blood lymphocytes were examined in patients on long-term therapy with methoxsalen and UV-A radiation (PUVA). Ten patients with psoriasis were selected because they had received a high exposure to PUVA therapy, i.e., more than 200 treatments over 2-6 years with cumulative exposure doses of 1700-6000 J/cm2 UV-A radiation. Results were compared to those obtained with lymphocytes from untreated patients and UV-B treated patients with psoriasis. The PUVA-treated patients had low levels of E rosette-forming cells in the peripheral blood and markedly impaired lymphocyte responses following stimulation with optimal and suboptimal doses of mitogens. The sensitivity of lymphocytes to in vitro treatment with PUVA was similar in the three groups of patients. The results of this study indicate that long-term PUVA therapy alters the function and cell-surface markers or distribution of lymphocytes.

show abstract

Section: Discussionmentioning

confidence: 54%

Abnormal lymphocyte function following long-term PUVA therapy for psoriasis

et al. 1983

View full text Add to dashboard Cite

show abstract

“…This phenomenon could be explained by the beneficial effects of UVA itself or by the contaminating UVB in the emitted lights. Alternatively, it may represent the systemic immunological effects of PUVA therapy, which have been previously demonstrated in patients with psoriasis undergoing 8MOP PUVA treatment (15)(16)(17).…”

Section: Discussionmentioning

confidence: 98%

Treatment of a Case of Mycosis Fungoides and One of Parapsoriasis en Plaque with Topical PUVA Using a Monofunctional Furocoumarin Derivative, 4,6,4'‐Trimethylangelicin

Morita

Takashima

Nagai

et al. 1990

The Journal of Dermatology

View full text Add to dashboard Cite

A case of plaque stage mycosis fungoides and one of parapsoriasis en plaque were treated with topical PUVA therapy using a monofunctional furocoumarin derivative, 4,6,4'-trimethylangelicin (TMA). Both patients showed complete clearance of eruptions within 16 treatments. The therapeutic effectiveness of TMA was confirmed by the fact that those eruptions exposed to UVA alone, without TMA application, showed slower and less significant improvement. Histologically, dermal infiltrates of mycosis cells and associated epidermotrophism disappeared almost completely in response to TMA PUVA. No side effects or changes in values in laboratory examinations were observed during treatment.

show abstract

“…These comprised: 90 with psoriasis, 27 with parapsoriasis, 19 with cutaneous T-cell lymphoma, 23 with vitiligo, eight with cutaneous mastocytosis, 16 with atopic dermatitis, three with prurigo nodularis, two with polymorphous light eruption and 10 with pruritus of chronic renal failure on dialysis, treated between 1977 and 1987 in our department. These comprised: 90 with psoriasis, 27 with parapsoriasis, 19 with cutaneous T-cell lymphoma, 23 with vitiligo, eight with cutaneous mastocytosis, 16 with atopic dermatitis, three with prurigo nodularis, two with polymorphous light eruption and 10 with pruritus of chronic renal failure on dialysis, treated between 1977 and 1987 in our department.…”

Section: Accepted For Publication 31 May 1989mentioning

confidence: 99%

Cutaneous and ocular side-effects of PUVA photochemotherapy-a 10-year follow-up study

Alfadley

Keczkes

1989

Clin Exp Dermatol

View full text Add to dashboard Cite

To record the potentially serious side-effects of melanoma and non-melanoma skin cancers and ocular damage following long-term PUVA chemotherapy, we re-examined 198 of 242 patients. These comprised: 90 with psoriasis, 27 with parapsoriasis, 19 with cutaneous T-cell lymphoma, 23 with vitiligo, eight with cutaneous mastocytosis, 16 with atopic dermatitis, three with prurigo nodularis, two with polymorphous light eruption and 10 with pruritus of chronic renal failure on dialysis, treated between 1977 and 1987 in our department. During the 10-year period, 11 patients died of unrelated disease. None of the patients reviewed had previous skin cancer or had been treated with arsenic, methotrexate or ionizing irradiation before PUVA treatment. None of the patients were children under 16 years of age. The mean age was 54.5 years, the sex ratio 102:96 (M:F). The mean cumulative dose of UVA for the whole group was 169.5 J/cm2. One patient with psoriasis, psoriatic arhropathy, ankylosing spondylitis and Crohn's disease, who was on azathioprine for 6 years, developed squamous-cell carcinoma on the left lower leg. Another patient with pustular psoriasis, who received PUVA treatment to her palms and soles only, developed malignant lentigo of Hutchinson on the right lower leg. PUVA lentigines were found in about 20% of patients. All patients had a yearly ophthalmological examination. None of them developed cataracts, lens opacities or had impairment of their visual acuity.

show abstract

Transient impairment of peripheral blood lymphocyte function during PUVA therapy

Cited by 44 publications

References 14 publications

Abnormal lymphocyte function following long-term PUVA therapy for psoriasis

Abnormal lymphocyte function following long-term PUVA therapy for psoriasis

Treatment of a Case of Mycosis Fungoides and One of Parapsoriasis en Plaque with Topical PUVA Using a Monofunctional Furocoumarin Derivative, 4,6,4'‐Trimethylangelicin

Cutaneous and ocular side-effects of PUVA photochemotherapy-a 10-year follow-up study

Contact Info

Product

Resources

About